Your session is about to expire
← Back to Search
mTOR Inhibitor
Pazopanib for Cancer
Phase 1
Waitlist Available
Led By David S Hong, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months
Awards & highlights
Study Summary
This trial is testing the combination of Votrient and Afinitor to see if the highest tolerable dose can be given to patients with advanced cancer. The safety of these drugs will also be studied.
Eligible Conditions
- Cancer
- Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Maximum Tolerated Dose (MTD) of Pazopanib and Everolimus
Secondary outcome measures
Response.of Pazopanib and Everolimus
Side effects data
From 2019 Phase 2 trial • 30 Patients • NCT0146697253%
Fatigue
50%
Nausea
37%
Diarrhea
33%
Back pain
30%
Hypertension
30%
Anorexia
23%
Abdominal pain
20%
Bone pain
17%
Dyspnea
17%
Vomiting
17%
Headache
17%
Aspartate aminotransferase increased
13%
Arthralgia
13%
Constipation
13%
Palmar-plantar erythrodysesthesia syndrome
13%
Alanine aminotransferase increased
13%
Investigations - Other
10%
Anemia
10%
Blurred vision
10%
Chills
10%
Pain in extremity
10%
Hot flashes
10%
Dysgeusia
10%
Rash maculo-papular
10%
Alkaline phosphatase increased
7%
Cough
7%
Urinary frequency
7%
White blood cell decreased
7%
Platelet count decreased
7%
Neutrophil count decreased
7%
Urinary tract pain
7%
Dry Mouth
7%
Urinary incontinence
7%
Skin and subcutaneous tissue disorders - Other
7%
Alopecia
7%
Gastroesophageal reflux disease
7%
Fever
7%
Dyspepsia
7%
Non-cardiac chest pain
7%
Hypothyroidism
7%
Hyperglycemia
7%
Hyponatremia
7%
Peripheral motor neuropathy
7%
Blood bilirubin increased
3%
Pleural effusion
3%
Hypotension
3%
Back Pain
3%
Thromboembolic event
3%
Heart Failure
3%
Small intestinal obstruction
3%
Vertigo
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pazopanib in Combination With a NSAI
Trial Design
1Treatment groups
Experimental Treatment
Group I: Pazopanib + EverolimusExperimental Treatment2 Interventions
Pazopanib 200 mg and Everolimus 5.0 mg oral dosing every other day (except for lead in 5 days of Cycle 1 where both drugs administered daily).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pazopanib
2012
Completed Phase 4
~1370
Everolimus
2010
Completed Phase 4
~1510
Find a Location
Who is running the clinical trial?
GlaxoSmithKlineIndustry Sponsor
4,748 Previous Clinical Trials
8,067,450 Total Patients Enrolled
National Comprehensive Cancer NetworkNETWORK
115 Previous Clinical Trials
7,573 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
2,962 Previous Clinical Trials
1,803,294 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger